Home  /  Resource Library  /  Addition of Rituximab to High-Dose Methotrexate Regimens Improves Complete Response Rates and Median Overall Survival in Non-Germinal Center Primary CNS Lymphoma

Addition of Rituximab to High-Dose Methotrexate Regimens Improves Complete Response Rates and Median Overall Survival in Non-Germinal Center Primary CNS Lymphoma

Results of a retrospective study examining the effect of adding rituximab to high dose methotrexate to treat primary central nervous system lymphoma.